Skip to content

Evaluating the role of misoprostol in labor induction

Evaluating the role of misoprostol in inducing vaginal births for singleton pregnancies

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12624001152516
Enrollment
313
Registered
2024-09-23
Start date
2022-12-02
Completion date
2023-12-01
Last updated
2024-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The study consisted of 2 groups. 25 mcg vaginal misprostol was applied to the patients in the intervention group for labor induction. Patients in the control group were followed up spontaneously. The results of both groups were compared.

Interventions

Since misoprostol is only indicated for postterm pregnant women for labor induction in our country, 25 mcg misoprostol was administered vaginally to women with a singleton pregnancy in vertex presentation, without previous uterine surgery, with a pregnancy of 42 weeks or more, and with a Bishop score of five and/or below. In patients with no response, the repeat dose was repeated a maximum of four times. Misoprostol was not administered to patients who did not want to receive labor induction or

Since misoprostol is only indicated for postterm pregnant women for labor induction in our country, 25 mcg misoprostol was administered vaginally to women with a singleton pregnancy in vertex presentation, without previous uterine surgery, with a pregnancy of 42 weeks or more, and with a Bishop score of five and/or below. In patients with no response, the repeat dose was repeated a maximum of four times. Misoprostol was not administered to patients who did not want to receive labor induction or who went into spontaneous labor. Misoprostol was administered by a gynecologist and obstetrician. After the patients were administered misoprostol, NST was monitored continuously for the first two hours and at two-hour intervals in the following period. After the application, all data such as the patients' delivery times, delivery methods, cesarean delivery indications, and induction dose numbers were recorded by the gynecologist.

Sponsors

Elmin Eminov
Lead SponsorIndividual

Study design

Allocation
Non-randomised trial
Primary purpose
Treatment

Eligibility

Sex/Gender
All
Age
18 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

singleton pregnancy fetus in cephalic presentation participants who consented to the study

Exclusion criteria

multiple pregnancy presence of uterine surgery malpresentation placenta previa asthma glaucoma disagreement to participate in the study

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026